Rejdak K, et al. - In a population of individuals with refractory myasthenia gravis (MG), researchers conducted this prospective open-label study to evaluate the efficacy of cladribine (2-chlorodeoxyadenosine) treatments. This investigation was carried out at the Department of Neurology, Medical University of Lublin during 2014– 2017 and was approved by the local ethics committee. In total, 11 individuals achieved significant clinical improvement in Myasthenia Gravis Composite (MGC) score during their therapy. Within 4 months of observation, the mean MGC score declined from 15.1 to 6.3 points. Prednisolone dosage declined from 9.5 to 1.9 mg. In the study period, none of the patients received treatments for intravenous immunoglobulin or plasma exchange, and no adverse events occurred. In a population of patients with refractory MG, cladribine seems to be a safe and effective emergency therapy.